Glioblastoma is the most common malignancy of the brain which carries a poor prognosis that has changed very little in the last few decades. The aim of my research is to test for effective and innovative treatment regimens to enhance cell death in glioblastoma by chemo/-radiosensitisation. This is tested using highly clinically relevant, patient-derived glioblastoma cells extracted from surgical biopsies from the Sheffield Teaching Hospitals which are cultured and grown in more clinically… Show more Glioblastoma is the most common malignancy of the brain which carries a poor prognosis that has changed very little in the last few decades. The aim of my research is to test for effective and innovative treatment regimens to enhance cell death in glioblastoma by chemo/-radiosensitisation. This is tested using highly clinically relevant, patient-derived glioblastoma cells extracted from surgical biopsies from the Sheffield Teaching Hospitals which are cultured and grown in more clinically recapturative 3D matrices to better predict the clinical response. Additionally HEA accredited as an associate fellow from my teaching and mentorship at both the pre and postgraduate levels Show less

Based in oncology and chemistry at the University of Sheffield and focused on the design and development of metal-based, light activated drugs to treat superficial cancers using more advanced photodynamic therapy.

In this role, I worked on analysing prostate and breast bone metastases and their response to alpha sourced radiotherapy in combination with DDR inhibitors. This involved the processing and scoring of IHC images in terms of their bone remodelling structure and IF imaging on DDR activation.